Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAspirus Arise pharmacy coverage update | OpenPayer
    Ask Trek AI about this page
    ModifiedAspirus ArisePolicy N/A

    September 2025 P&T formulary decisions (partial) — Pharmacy & Specialty Drugs coverage criteria

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Summarizes Pharmacy & Therapeutics Committee decisions on formulary status, new indications, generics, and dosage-form launches for multiple drugs that affect Aspirus Medicare formulary placement and prior authorization/step therapy rules.

    Policy Summary
    PayerAspirus Arise
    PolicySeptember 2025 P&T formulary decisions (partial)
    Policy CodePolicy N/A
    Change TypeFormulary assignments & new launches
    Effective DateFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain prior authorization when prescribing products listed as 'Formulary w/PA' or submit required documentation for age/indication expansions effective 01/01/2026.
    SourceLink
    POLICY UPDATE CHANGES

    New strengths and formulations for Zoryve (roflumilast) were released to support pediatric use and new indications, and were assigned formulary statuses.

    New 5 mg and 7.5 mg selumetinib (Koselugo) sprinkle capsules were launched to support pediatric patients ≥1 year; Koselugo listed as Formulary.

    New vial size for Krystexxa (pegloticase) — 8 mg/50 mL IV vial — was launched and listed as Non-Formulary.

    New Evexithroid (thyroid) tablet strengths (45 mg and 75 mg) were launched and listed as Non-Formulary.

    Vyscoxa (celecoxib) 10 mg/mL oral suspension launched and listed as Non-Formulary.

    Tonmya (cyclobenzaprine) 2.8 mg sublingual tablet for fibromyalgia launched and listed as Non-Formulary.

    Beizray (docetaxel-albumin) 80 mg/4 mL IV vials approved via 505(b)(2) pathway and listed as Non-Formulary.

    Keytruda Qlex (pembrolizumab-berahyaluronidase alfa) subcutaneous formulation launched and listed as Non-Formulary.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ~40drugs or entries listed in this excerpt
    Multiplenew strengths/formulations launched
    Severalitems designated Non-Formulary
    FormularyKoselugo designation
    01/01/2026Formulary changes effective

    Formulary Placement & Coverage Decisions

    Formulary placement decisions (examples)

    P&T recommendations (selected examples from this excerpt):

    Selected Non-Formulary entries: Tryptyr (acoltremon) for dry eye disease; Vanrafia (atrasentan) for reduction of proteinuria in IgAN; Vykat XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome; Zelsuvmi (berdazimer) for molluscum contagiosum; Leqvio (inclisiran) for LDL reduction; multiple specialty oncology and immunology agents and certain expanded indications listed as Non-Formulary (examples include Tecentriq ± Hybreza combinations for ES-SCLC post‑induction, Praluent autoinjectors for HeFH/HoFH, Vonvendi expanded IV vials, Evkeeza age expansion, and others where noted).

    Non-Formulary status recorded in entries

    Formulary w/PA or Formulary entries: Selected agents recommended as Formulary or Formulary w/PA include Avmapki Fakzynja (avutometinib/defactinib), Romvimza (vimseltinib), Gomekli (mirdametinib), Ibtrozi (taletrectinib) (all listed Formulary w/PA for specified oncology indications); Sirturo (bedaquiline) age expansion listed Formulary; Brukinsa (zanubrutinib) 160 mg tablets listed Formulary; Dexcom G7 15-day sensor listed Formulary; Koselugo (selumetinib) 5 mg and 7.5 mg sprinkle capsules listed Formulary for pediatric NF1 expansion.

    Formulary decisions vary by product and indication

    New generics and dosage forms: Numerous launches and new dosage strengths/forms were reviewed with recommendations that often favor lower‑cost generics or retain prior placement: examples include new generics and formulations (Vuity generic, generic bosentan ODT, Kirsty biosimilar insulin aspart, generic glycerol phenylbutyrate), new Dexcom G7 15‑day sensor (Formulary), and multiple new tablet/suspension strengths (Evexithroid 45 & 75 mg listed Non‑Formulary; Vyscoxa 10 mg/mL oral suspension listed Non‑Formulary). The committee noted an effective date of 01/01/2026 for formulary changes related to new generics/new indications where specified.

    Effective date for such changes noted as 01/01/2026 in part

    The P&T Committee excerpt records multiple products explicitly designated Non-Formulary in the reviewed entries. Examples in this document include expanded-indication listings for Vonvendi (von Willebrand factor [recombinant]) IV vials, certain oncology and specialty agents in combination regimens (e.g., Tecentriq/Tecentriq Hybreza with Zepzelca for ES-SCLC), and newly launched strengths or formulations such as the Krystexxa 8 mg/50 mL IV vial, Evexithroid 45 & 75 mg tablets, Vyscoxa 10 mg/mL oral suspension, Tonmya 2.8 mg sublingual tablet, Beizray 80 mg/4 mL IV vials, and the subcutaneous Keytruda Qlex. These entries are recorded as Non-Formulary unless otherwise noted.

    Select items explicitly called out as Non-Formulary in the committee notes include: Vonvendi (650 & 1300-unit IV vials) for expanded prophylactic and perioperative use; Opzelura 1.5% cream for pediatric atopic dermatitis; combination regimens listed as Non-Formulary such as Tecentriq/Tecentriq Hybreza with Zepzelca; Uzedy risperidone prefilled syringes for bipolar I; weight-loss agents for specific indications (e.g., Wegovy for noncirrhotic MASH); newly launched products and strengths recorded as Non-Formulary including Krystexxa 8 mg/50 mL IV vial, Evexithroid 45 & 75 mg tablets, Vyscoxa 10 mg/mL oral suspension, Tonmya 2.8 mg sublingual tablet, Beizray 80 mg/4 mL IV vials, and Keytruda Qlex subcutaneous vials.

    Within the provided excerpt there are no sentences that explicitly frame any of these entries using the phrase 'not medically necessary' or present an explicit medical-necessity rationale denying coverage. The document records formulary recommendations (Formulary, Formulary w/PA, or Non-Formulary) and supporting rationale/alternatives for some items (for example, Dexcom G7 rationale and generic alternatives for Vyscoxa), but does not include explicit 'not medically necessary' determination language in the cited passages.

    Prior Authorization, Step Therapy & Documentation

    Prior Authorization

    Formulary Status & Prior Authorization

    Formulary status determines PA requirements: items designated as Formulary w/PA require prior authorization as noted; new formulations or strengths follow the formulary designation for PA needs. Effective date: 01/01/2026 — ensure documentation supports the change and date for any submissions.

    • Formulary w/PA = prior authorization required for covered agents and new formulations/strengths.
    • Formulary status drives whether a PA is needed for new strengths or formulations (status of the new product controls PA requirement).
    • Effective date for formulary changes to New Generics, New Indications and Miscellaneous Previously Reviewed drugs: 01/01/2026.
    Denial Risk

    Non‑Formulary — Denial Risk

    Non-Formulary status may trigger denial: items listed as Non-Formulary are at higher risk for coverage denial unless an exception is granted; providers should submit complete supporting documentation.

    Step Therapy & Preferred-Drug Sequencing

    AgentCoverage StatusPrior Authorization (PA) RequiredStep Therapy / Notes
    Avmapki Fakzynja (avutometinib/defactinib)
    Formulary w/PA
    Yes — Formulary w/PA designation indicates PA required
    May be subject to step therapy per plan-specific rules; specific ST not enumerated in excerpt
    AgentCoverage StatusPrior Authorization (PA) RequiredStep Therapy / Notes
    Vyscoxa (celecoxib) 10 mg/mL oral suspension
    Non-Formulary
    PA likely required for Non-Formulary products unless separate policy applies
    Preference for lower-cost generic celecoxib capsules (can be opened and mixed) referenced; generics may be preferred prior to covering branded suspension

    Administration Site & Provider-Administered Formulations

    Note

    New IV vials and autoinjectors noted — site‑specific rules not detailed

    Several new IV vial and autoinjector formulations were noted (e.g., new Krystexxa vial size, new branded autoinjectors), but site‑of‑care or infusion‑center specific rules were not specified in the provided excerpt.

    Note

    Keytruda Qlex SC is provider‑administered over 1–2 minutes — site‑of‑care implications

    Keytruda Qlex is a new subcutaneous, provider‑administered formulation that can be given over approximately 1–2 minutes instead of a 30‑minute IV infusion; providers should note site‑of‑care implications for administration scheduling and billing.

    • Keytruda Qlex (pembrolizumab‑berahyaluronidase alfa) SQ allows administration over 1–2 minutes but remains healthcare provider administered.

    Abbreviations & Notable Product Notes

    PA (Prior Authorization) definition entry
    TermPA
    DefinitionPrior Authorization
    Context notePA status is assigned to drugs by the P&T committee and indicates a provider must obtain approval before coverage is allowed.
    QL (Quantity Limit) definition entry
    TermQL
    DefinitionQuantity Limit
    Context noteQL indicates restrictions on the amount or frequency of a medication that will be covered within a given time period.

    Policy Context & Scope

    This record documents the Pharmacy & Therapeutics Committee review process and its recommendations related to formulary placement, new indications, newly launched generics and dosage forms, and related dosing or age-expansion considerations. Committee entries identify which products should be placed as Formulary, Formulary w/PA, or Non-Formulary, and note effective dates, age or indication expansions, and when lower-cost generics are preferred—information intended to guide subsequent prior authorization, step therapy, and coverage implementation decisions.

    Policy Summary
    PayerAspirus Arise
    PolicySeptember 2025 P&T formulary decisions (partial)
    Policy CodePolicy N/A
    Change TypeFormulary assignments & new launches
    Effective DateFeb 1, 2026
    Next Review DateFeb 1, 2026
    Key ActionObtain prior authorization when prescribing products listed as 'Formulary w/PA' or submit required documentation for age/indication expansions effective 01/01/2026.
    SourceLink
    On This Page
    Formulary Placement & Coverage DecisionsPrior Authorization, Step Therapy & DocumentationStep Therapy & Preferred-Drug SequencingAdministration Site & Provider-Administered FormulationsAbbreviations & Notable Product NotesPolicy Context & Scope
    • Non-Formulary designations commonly result in claim denials without an approved exception or justification.
    • When a product is Non-Formulary, include clinical rationale and prior therapies attempted to support any medical necessity request.
    Denial Risk

    Examples of Non‑Formulary Items at Risk for Denial

    Specific Non-Formulary items called out in the P&T notes may be denied: examples include Krystexxa 8 mg/50 mL vial, new Evexithroid strengths (45 mg, 75 mg), Vyscoxa oral suspension, and Tonmya sublingual tablets — plan accordingly.

    • Krystexxa (pegloticase) 8 mg/50 mL IV vial — Non‑Formulary and may be denied.
    • Evexithroid (thyroid) 45 & 75 mg tablets — Non‑Formulary and may be denied.
    • Vyscoxa (celecoxib) 10 mg/mL oral suspension — Non‑Formulary and may be denied.
    • Tonmya (cyclobenzaprine) 2.8 mg sublingual tablet — Non‑Formulary and may be denied.
    Note

    Cost & Lower‑Cost Alternative Context

    Cost/context notes — include pricing and lower‑cost alternatives when available to support step or exception requests.

    • Vyscoxa 473 mL bottle WAC = $2,895.49; generic celecoxib capsules with MAC pricing (~$0.15 to ~$1.10) are preferred lower‑cost alternatives.
    • Tonmya maintenance dosing cost example: approximately $1,860 per month; consider generic cyclobenzaprine formulations when clinically appropriate.
    Note

    Preferred Generic Alternatives

    Preferred generic alternatives: when generics exist (e.g., celecoxib capsules), prefer those lower‑cost options and document why a brand or novel formulation is necessary if requesting coverage.

    • If a generic alternative is available and clinically appropriate (for example, generic celecoxib capsules), the generic should be used or documented rationale provided for the brand/special formulation.
    • Opening generic capsules and administering with food (e.g., applesauce) may be a clinically appropriate, cost‑effective alternative to oral suspensions in some patients.
    Step Therapy

    Step Therapy Note

    Step therapy referenced in the P&T key (ST = Step Therapy); specific step rules may exist elsewhere in the policy — check plan-specific step therapy criteria when submitting authorizations.

    • ST in the key indicates step therapy may apply; consult the detailed step therapy rules (not included in this excerpt) for agent‑specific requirements.
    Documentation Required

    Documentation Required for PA/Exceptions

    Documentation reminder: include clinical history, prior therapies tried, and dates to support PA or exception requests; reference the effective dates and pricing context when relevant.

    • Provide prior treatment history and rationale for use of Non‑Formulary or high‑cost formulations.
    • Reference effective dates (e.g., 01/01/2026 for many formulary changes) in requests to align with P&T decisions.
    ST (Step Therapy) definition entry
    TermST
    DefinitionStep Therapy
    Context noteST denotes a requirement to try specified preferred or lower‑cost therapies before a non-preferred medication will be approved.
    Zoryve (roflumilast) — new topical strengths/formulations
    DrugZoryve (roflumilast)
    New strengths/formulations0.05% cream for atopic dermatitis in children aged 2-5 years; 0.3% foam (and 0.3% cream referenced) for plaque psoriasis of scalp & body and seborrheic dermatitis.
    P&T placement noteNew strengths released to support pediatric use and new indications; 0.3% formulation listed as Non-Formulary in committee decision.
    Koselugo (selumetinib) — new sprinkle capsule strengths
    DrugKoselugo (selumetinib) sprinkle capsules
    New strengths5 mg and 7.5 mg oral sprinkle capsules
    Indication / age expansionLaunched to support neurofibromatosis type 1 age expansion for pediatric patients ≥ 1 year of age; listed as Formulary by the committee.